IMAGE: Lung squamous cell carcinoma

Breaking News

Key: Meeting M      Journal J      Funder F

Showing releases 1126-1150 out of 1385.

<< < 41 | 42 | 43 | 44 | 45 | 46 | 47 | 48 | 49 | 50 > >>

Public Release: 10-Feb-2016
Journal of Physiology
Faulty bioelectric signal responsible for facial defects caused by rare genetic disorder
Tufts University biologists have discovered that faulty bioelectric signaling is responsible for the skull and facial abnormalities that characterize the rare genetic disorder Andersen-Tawil syndrome (ATS). The finding shows it may be possible to alter bioelectrical signaling to correct effects of fetal alcohol syndrome and other developmental defects or genetic mutations.
National Science Foundation, Defense Advanced Research Projects Agency, National Institutes of Health

Contact: Kim Thurler
kim.thurler@tufts.edu
617-627-3175
Tufts University

Public Release: 10-Feb-2016
Cell Host & Microbe
Inhibiting age-related inflammation maintains healthy gut microbiota and extends lifespan
New research shows that age-related inflammation drives changes in the fruit fly gut-causing metaplasia or abnormal changes in cells. That metaplasia led to changes in the microbiota, which resulted in pathology and shorter lifespans. Researchers reduced inflammatory signaling in the gastric region of the fly gut, preventing metaplasia, maintaining a healthy commensal population, and extending lifespan in the flies by up to 18 percent. Metaplasias have been associated with human cancers and other diseases.
NIH/National Institute on Aging, NIH/National Institute on General Medical Sciences and American Federation for Aging Research

Contact: Kris Rebillot
krebillot@buckinstitute.org
415-209-2080
Buck Institute for Research on Aging

Public Release: 9-Feb-2016
Cancer Research
Some heart drugs and antibiotics show effective in fighting cancer
North American researchers have identified drugs that showed promising perspectives in treating cancers, according to a recent study published in Cancer Research. These drugs are normally used to treat other diseases, such as heart failure, cardiac arrhythmia, and infections.
F. M. Kirby Foundation, National Institutes of Health

Contact: Marise Daigle
marise.daigle@recherche-ste-justine.qc.ca
514-345-4931 x3256
University of Montreal

Public Release: 9-Feb-2016
Science Signaling
Scientists discover how breast cancer cells spread from blood vessels
Researchers have identified a protein that controls how breast cancer cells spread around the body.

Contact: Fiona Dennehy
fionadennehy@cancer.org.uk
44-020-346-96770
Cancer Research UK

Public Release: 9-Feb-2016
Cell Reports
WSU researchers see helpful protein causing cancer
Washington State University researchers have determined how a protein that helps cells fight viruses can also cause genetic mutations that lead to cancer.
National Institutes of Health

Contact: Steven Roberts
sroberts@vetmed.wsu.edu
509-335-4934
Washington State University

Public Release: 9-Feb-2016
Developmental Cell
Cells with an incorrect number of chromosomes lead to tumor development
A study conducted at IRB Barcelona on the fly Drosophila reveals how surviving aneuploid cells favor tumor development.

Contact: Sònia Armengou
armengou@irbbarcelona.org
34-934-037-255
Institute for Research in Biomedicine (IRB Barcelona)

Public Release: 9-Feb-2016
Proceedings of the National Academy of Sciences
Wayne State University researchers discover new source of mutations in cancer
Recently, a new mutation signature found in cancer cells was suspected to have been created by a family of enzymes found in human cells called the APOBEC3 family. The study, 'Strand-biased Cytosine deamination at the Replication Fork causes Cytosine to Thymine Mutations in Escherichia coli,' led by Ashok Bhagwat, Ph.D., professor of chemistry in the College of Liberal Arts and Sciences at Wayne State University, was recently published in the Proceedings of the National Academy of Sciences.
National Institutes of Health

Contact: Julie O'Connor
julie.oconnor@wayne.edu
313-577-8845
Wayne State University - Office of the Vice President for Research

Public Release: 9-Feb-2016
Proceedings of the National Academy of Sciences
'Molecular movie' opens door to new cancer treatments
An international team of scientists led by the University of Liverpool has produced a 'structural movie' revealing the step-by-step creation of an important naturally occurring chemical in the body that plays a role in some cancers.

Contact: Nicola Frost
nicola.frost@liverpool.ac.uk
University of Liverpool

Public Release: 9-Feb-2016
International Journal of Radiation Oncology • Biology • Physics
New study finds interruption of radiation therapy risks cancer recurrence
Cancer patients who miss two or more radiation therapy sessions have a worse outcome than fully compliant patients, investigators at Montefiore Einstein Center for Cancer Care and Albert Einstein College of Medicine's NCI-designated Albert Einstein Cancer Center have found. The study, published in the International Journal of Radiation Oncology Biology Physics, suggests that this noncompliance to scheduled treatments may represent a new behavioral biomarker for identifying high-risk patients who require additional interventions to achieve optimal care outcomes.

Contact: Tracy Gurrisi
TGurrisi@Montefiore.org
718-920-8274
Albert Einstein College of Medicine

Public Release: 9-Feb-2016
eLife
Penn researchers illuminate 'dark side' of the transcriptome
A new way of mapping the collection of RNA read-outs that are expressed by a cell's active genes has been devised to shed additional light on the role of RNAs in cells. These 'dark' variations in RNA likely have roles in gene regulation across tissues, development, and in human diseases. The team will use the now-free software to interrogate cells in brain disorders, cancers, and other illnesses.
National Institutes of Health, Penn Medicine Neuroscience Center

Contact: Karen Kreeger
karen.kreeger@uphs.upenn.edu
215-349-5658
University of Pennsylvania School of Medicine

Public Release: 8-Feb-2016
Nature Structural & Molecular Biology
Scientists propose 'pumpjack' mechanism for splitting and copying DNA
New close-up images of the proteins that copy DNA inside the nucleus of a cell have led a team of scientists to propose a brand new mechanism for how this molecular machinery works. The scientists studied proteins from yeast cells, which share many features with the cells of complex organisms such as humans, and could offer new insight into ways that DNA replication can go awry.
National Institutes of Health, Howard Hughes Medical Institute, Brookhaven Lab Biology Department

Contact: Karen McNulty Walsh
kmcnulty@bnl.gov
631-344-8350
DOE/Brookhaven National Laboratory

Public Release: 8-Feb-2016
Proceedings of the National Academy of Sciences
Yale study examines evolution of cancer
A novel Yale study answers age-old questions about how cancers spread by applying tools from evolutionary biology. The new insights will help scientists better understand the genetic origins of tumor metastases, and lead to more effective targets for treatment, said the researchers.
Gilead Sciences, Inc.

Contact: Ziba Kashef
ziba.kashef@yale.edu
203-436-9317
Yale University

Public Release: 8-Feb-2016
Cancer
Study compares effectiveness of phone-based and web-based smoking cessation programs in four states
A new analysis indicates that states' Web-based and phone-based tobacco cessation programs can help people quit smoking, but certain personal characteristics may lead individuals to prefer one type of program over the other.

Contact: Dawn Peters
sciencenewsroom@wiley.com
781-388-8408
Wiley

Public Release: 8-Feb-2016
Cancer Cell
Scientists discover a unique mechanism for a high-risk leukemia
Researchers uncovered the aberrant mechanism underlying a notoriously treatment-resistant acute lymphoblastic leukemia subtype; findings offer lessons for understanding all cancers.
NIH/National Cancer Institute, Stand Up to Cancer Innovative Research Grant, St. Baldrick's Foundation, Leukemia and Lymphoma Society, Lady Tata Memorial Trust Award, Alex's Lemonade Stand Foundation, ALSAC

Contact: Frannie Marmorstein
media@stjude.org
901-595-0221
St. Jude Children's Research Hospital

Public Release: 8-Feb-2016
Phase 3 trial with PM1183 in OC continues on the basis of positive recommendation by IDMC
The Independent Data Monitoring Committee (IDMC) has notified PharmaMar of its recommendation that the Phase III (CORAIL) trial currently under way with PM1183 in platinum-resistant ovarian cancer patients should continue without any changes.
PharmaMar

Contact: Paula Fernández
pfalarcon@pharmamar.com
34-638-796-215
Pharmamar

Public Release: 8-Feb-2016
Proceedings of the National Academy of Sciences
Device hits pancreatic tumors hard with toxic 4-drug cocktail, sparing the body
A powerhouse team of researchers at the University of North Carolina at Chapel Hill has revealed that an implantable device can deliver a particularly toxic cocktail of drugs directly to pancreatic tumors to stunt their growth or in some cases, shrink them -- all while showing signs that the rest of the body would be spared toxic side effects.
University Cancer Research Fund at UNC, National Defense Science and Engineering Graduate Fellowship, UNC Medical Scientists Training Program, PhRMA Foundation Fellowship

Contact: Thania Benios
thania_benios@unc.edu
919-962-8596
University of North Carolina at Chapel Hill

Public Release: 8-Feb-2016
Gastroenterology
Nanoparticle therapy that uses LDL and fish oil kills liver cancer cells
An experimental nanoparticle therapy that combines low-density lipoproteins (LDL) and fish oil preferentially kills primary liver cancer cells without harming healthy cells, UT Southwestern Medical Center researchers report.
American Gastroenterological Association/Research Foundation Scholar Award, Southwestern Small Animal Imaging Research Program, NIH/National Cancer Institute, UT Southwestern/President's Research Council Award

Contact: Deborah Wormser
deborah.wormser@utsouthwestern.edu
214-648-3404
UT Southwestern Medical Center

Public Release: 8-Feb-2016
Molecular Cell
More detailed analysis of how cells react to stress
Stress in the body's cells is both the cause and consequence of inflammatory diseases or cancer. The cells react to stress to protect themselves. Researchers at the University of Zurich have now developed a new technique that allows studying a fundamental response to stress in much more detail than previously possible: the ADP-ribosylation of chromatin. In the long term, this method could help finding ways of blocking disease-causing processes.

Contact: Michael O. Hottiger
hottiger@dmmd.uzh.ch
41-446-355-474
University of Zurich

Public Release: 7-Feb-2016
Journal of Urology
Removal of complex renal tumors performed safely by robotic surgery in selected patients
Renal cell carcinoma can sometimes spread to the inferior vena cava (IVC), the body's largest vein, posing a threat to the heart and brain. Robotic nephrectomy for inferior vena cava tumor thrombus has favorable outcomes in selected patients compared with open surgery, which can have a high rate of complications, report surgeons in The Journal of Urology®.

Contact: Eileen Leahy
jumedia@elsevier.com
732-238-3628
Elsevier Health Sciences

Public Release: 5-Feb-2016
Oncotarget
Gene family turns cancer cells into aggressive stem cells that keep growing
An examination of 130 gene expression studies in 10 solid cancers has found that when any of four related genes is overexpressed, patients have much worse outcomes, including reduced survival.
NIH/National Cancer Institute, American Cancer Society Institutional Research Grant

Contact: Karen Teber
km463@georgetown.edu
Georgetown University Medical Center

Public Release: 5-Feb-2016
Journal of Molecular Biology
NIH researchers identify striking genomic signature shared by 5 types of cancer
National Institutes of Health researchers have identified a striking signature in tumor DNA that occurs in five different types of cancer. The specific signature results from a chemical modification of DNA called methylation, which can control the expression of genes like a dimmer on a light switch. Based on this advance, the researchers hope to spur development of a blood test that can be used to diagnose a variety of cancers at early stages.

Contact: Jeannine Mjoseth
Mjosethj@mail.nih.gov
301-402-0911
NIH/National Human Genome Research Institute

Public Release: 5-Feb-2016
Bone Marrow Transplantation
Cancer treatment: Therapeutic approach gives hope for the treatment of multiple myeloma
A new therapeutic approach tested by a team from Maisonneuve-Rosemont Hospital and the University of Montreal gives promising results for the treatment of multiple myeloma, a cancer of the bone marrow currently considered incurable with conventional chemotherapy. The study resulted in a total cure rate of 41 percent, a record level using this strategy. Moreover, patients in complete remission six months after the allograft had a relapse-free survival rate of 60 percent.
University of Montreal's William Brock Fund

Contact: Julie Gazaille
j.cordeau-gazaille@umontreal.ca
University of Montreal

Public Release: 5-Feb-2016
Pediatric Blood and Cancer
Experts establish standards for psychosocial care of children with cancer and their families
Children with cancer and their families often experience considerable psychological and social challenges during and after treatment. A special issue of Pediatric Blood & Cancer now offers evidence-based standards for pediatric psychosocial care.

Contact: Dawn Peters
sciencenewsroom@wiley.com
781-388-8408
Wiley

Public Release: 5-Feb-2016
Cancer Prevention Research
Possible marker for recurring HPV-linked oropharyngeal cancers
A look-back analysis of HPV infection antibodies in patients treated for oropharyngeal (mouth and throat) cancers linked to HPV infection suggests at least one of the antibodies could be useful in identifying those at risk for a recurrence of the cancer, say scientists at The Johns Hopkins University. A report on the study is published in the February issue of Cancer Prevention Research.
Oral Cancer Foundation, NIH/National Institute of Dental and Craniofacial Research

Contact: Vanessa Wasta
wasta@jhmi.edu
410-614-2916
Johns Hopkins Medicine

Public Release: 5-Feb-2016
Cancer Discovery
Single-lesion biopsy may be insufficient to choose therapy targeting resistance mutations
When metastatic tumors driven by drug-targetable genetic mutations become resistant to a targeted therapy drug, the usual practice is to test a single metastatic lesion for new mutations that can guide the selection of next-line therapies. But this strategy may miss additional targetable mutations that arise in different metastases, a new study finds.
NIH/National Cancer Institute, Damon Runyon Foundation

Contact: Katie Marquedant
kmarquedant@partners.org
617-726-0337
Massachusetts General Hospital

Showing releases 1126-1150 out of 1385.

<< < 41 | 42 | 43 | 44 | 45 | 46 | 47 | 48 | 49 | 50 > >>

  Search News Releases

     

 

EurekAlert!